Navigation Links
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
Date:3/20/2008

- By targeting interleukin-6 receptors, ACTEMRA provides significant

benefits for patients when compared with existing therapies -

NUTLEY, N.J., March 20 /PRNewswire/ -- Patients with rheumatoid arthritis treated with Roche's ACTEMRA(TM) (tocilizumab) experienced significant and rapid reduction in the signs and symptoms of their disease, according to a study published in this week's issue of The Lancet. Results from the OPTION (TOcilizumab Pivotal Trial in Methotrexate Inadequate respONders) trial -- a Phase III international study -- demonstrated that RA patients achieved greater improvement of symptoms and a higher quality-of-life with ACTEMRA, an interleukin-6 (IL-6) receptor inhibitor, in combination with methotrexate, compared with methotrexate plus placebo.

"Results of this pivotal study convincingly demonstrate that tocilizumab can effectively and rapidly diminish the painful and debilitating effects of rheumatoid arthritis," said Josef Smolen, M.D., lead investigator of the OPTION trial and Professor of Medicine at the Department of Internal Medicine at the Medical University of Vienna, Austria. "These trial findings are significant because we know that many rheumatoid arthritis patients continue to experience symptoms of joint pain, stiffness, physical disability and fatigue, despite treatment with existing therapies."

About OPTION Study

In the OPTION trial, a three-arm, double-blind, controlled Phase III study, 623 patients were randomized to receive ACTEMRA intravenously (either 4mg/kg or 8mg/kg) every four weeks plus methotrexate weekly or placebo infusions plus methotrexate weekly. The study was conducted in 73 trial sites in 17 countries outside the United States.

At 24 weeks, 58.5% of ACTEMRA patients (8mg/kg) achieved a 20% reduction in RA symptoms (ACR20)(1), compared with 26.5% of patients in placebo plus methotrexate patients. In the study, 43.9% of patients treated with ACTEMRA (8mg/kg) plus meth
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 An aggressive ... helped cut the rate of infection with a dangerous ... percent. Clostridium difficile, or C.diff, is a ... life-threatening inflammation of the colon. A recent article in ... Clostridium difficile Infection in the United States ...
(Date:2/27/2015)... Feb. 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" ... today announced financial results for its first quarter ended ... months ended December 31, 2014, revenue was $1,336,685. Operating ... $229,820 or $0.02 per share.  Covalon,s ... am very pleased with the significant progress we have ...
(Date:2/27/2015)... 2015  Bionik Laboratories Corp. (OTC:DWTPD), a ... it acquired Bionik Laboratories, Inc., a Toronto ... to qualified accredited investors of units consisting of its ... approximately $6.2 million. Shares of the Company,s common stock ... under the symbol "DWTPD" until FINRA,s approval of the ...
Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
... West Pharmaceutical Services, Inc. (NYSE: WST ) today ...  Summary comparative results were as follows: ($ millions, except per-share ... $ 281.8Gross Profit , 84.6 , 83.2Reported Operating Profit , ... 30.5 , 30.9Reported Diluted EPS , $ 0.57 , $ ...
... SEATTLE, July 28, 2011 Cell Therapeutics, Inc. ("CTI" or ... its efforts to develop its late stage oncology pipeline to ... ended June 30, 2011. "In the second quarter, ... the FDA,s Office of New Drugs ("OND") in allowing us ...
Cached Medicine Technology:West Announces Second Quarter 2011 Results 2West Announces Second Quarter 2011 Results 3West Announces Second Quarter 2011 Results 4West Announces Second Quarter 2011 Results 5West Announces Second Quarter 2011 Results 6West Announces Second Quarter 2011 Results 7West Announces Second Quarter 2011 Results 8West Announces Second Quarter 2011 Results 9West Announces Second Quarter 2011 Results 10West Announces Second Quarter 2011 Results 11West Announces Second Quarter 2011 Results 12West Announces Second Quarter 2011 Results 13West Announces Second Quarter 2011 Results 14West Announces Second Quarter 2011 Results 15West Announces Second Quarter 2011 Results 16Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 2Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 3Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 4Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 5Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 6
(Date:2/28/2015)... 28, 2015 A case management conference ... that have been filed by law firms including Bernstein ... in March, the Firm notes. , According to ... in the federal litigation will meet on March 13, ... prescription therapy treatments designed to raise levels of the ...
(Date:2/28/2015)... Ohio (PRWEB) February 28, 2015 ... Motivational? Supportive? Strategic? , There are all kinds ... strengths. To raise awareness of the advantages and ... firm PeopleKeys is launching a new product this ... clients better understand the connection between personality type, ...
(Date:2/28/2015)... The noted Friedman Dental Group of South ... relaunched their website. The new version of the site ... new section about their team members. Potential and current ... of each Friedman Dental Group team member including new ... to provide our patients with the opportunity to get ...
(Date:2/28/2015)... 28, 2015 Developers of FCPX ... new overlay plugin for Final Cut Pro X entitled FCPX ... Overlay Chromatic gives users total control over 6k lens dirt ... of Pixel Film Studios. “FCPX Overlay Chromatic was professionally designed ... use interface.” , FCPX Overlay Chromatic Grunge 6K is a ...
(Date:2/28/2015)... “ Powermod ” was featured on NewsWatch as ... at the latest and coolest technology products and services available ... a technology expert, conducted the review and shared with viewers ... Getting stuck with a low battery and no way to ... face on a daily basis. Even when a person does ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2
... A major research company with expertise in managing clinical ... Medical Campus to more efficiently bring the latest stem ... formally known as the Colorado Prevention Center, officially moved ... from the campus on Friday., It is the ...
... poor judges of their patients, health beliefs, according to ... A&M University and Paul Haidet from The Pennsylvania State ... is better the more patients are involved by asking ... for care. Their analysis 1 of how ...
... undergo cardiopulmonary bypass (CPB) during surgery for less ... suffer any impairments in neurocognitive abilities, such as ... Researchers from The Children,s Hospital of Philadelphia, in ... Pediatrics , reported on neuropsychological effects after surgery ...
... , , , , ... AUDIO: Scientists at Washington University School of Medicine in St. ... Click here for more information. , , ... , , , , , , ...
... Gardner HealthDay Reporter , THURSDAY, July 22 (HealthDay ... favorite pastimes -- sitting around -- the shorter their average ... remained even after researchers factored out obesity or the level ... a study of more than 120,000 American adults. It,s ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, July ... face a greater risk of having a stillborn child if ... treatments, a new study finds. Although neither boys nor ... that might affect their offspring, radiation damage to the uterus ...
Cached Medicine News:Health News:University of Colorado joins with major research firm to partner on stem cell research 2Health News:Doctors don't 'get' their patients 2Health News:Heart bypass for uncomplicated heart surgery does not reduce neurocognitive function in children 2Health News:Inhibiting fatty acids in immune cells decreases atherosclerosis risk 2Health News:Inhibiting fatty acids in immune cells decreases atherosclerosis risk 3Health News:Inhibiting fatty acids in immune cells decreases atherosclerosis risk 4Health News:The Longer You Sit, the Shorter Your Life Span: Study 2Health News:Radiation for Childhood Cancer Can Boost Risk of Stillbirth Later 2Health News:Radiation for Childhood Cancer Can Boost Risk of Stillbirth Later 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: